MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory
- Details
- Category: AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK.
Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, have announced an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine, in early clinical development for the treatment of lung cancer.
Bristol-Myers Squibb and Pfizer announce charitable donations of more than $1 million to support cardiovascular education
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced charitable donations totaling more than $1 million to be granted between 2014 and 2016 to seven nonprofit organizations that support patients with cardiovascular disease.
Merck to acquire Sigma-Aldrich to enhance position in attractive life science industry
- Details
- Category: Merck Group
Merck, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich today announced that they have entered into a definitive agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion (€13.1 billion), establishing one of the leading players in the $130 billion global life science industry.
AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer's disease
- Details
- Category: AstraZeneca
AstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.
Roche again ranked most sustainable healthcare company in the Dow Jones Sustainability Indices
- Details
- Category: Roche
For the sixth consecutive year, Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognised by the Dow Jones Sustainability Indices (DJSI) as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry. This places Roche amongst the top 10 percent of companies across all surveyed industries.
GSK joins with research councils in UK and South Africa to tackle non-communicable diseases
- Details
- Category: GlaxoSmithKline
GSK has announced a £5m collaboration with the UK and South African Medical Research Councils, to support much-needed research into non-communicable diseases (NCDs) in Africa, as part of GSK's Africa NCD Open Lab initiative.
More Pharma News ...
- Safety and sustained benefits of Adempas® from Bayer confirmed by results of long-term studies
- AstraZeneca and Redx Pharma agree research collaboration
- Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
- New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
- Ebola vaccine trials fast-tracked by international consortium
- Pfizer and Merck to collaborate on study evaluating novel anti-cancer combination regimen
- Roche and InterMune reach definitive merger agreement